- Trial phase
- Approved
- Time to market
- Already approved and marketed (FDA approval August 2018).
- Why 4/10
- Galafold is already FDA-approved (August 2018) and commercially marketed with no pending PDUFA or pivotal readout. The next potential catalyst is the Phase 3b pediatric trial (NCT06904261) in children aged 2-12, but that is likely 12+ months from completion. As an approved drug within a diversified portfolio, impactScore is capped at 4 per the rubric.
Galafold has no near-term binary catalyst; the next event to watch is the ongoing Phase 3b pediatric trial (NCT06904261), which could support a label expansion to children aged 2-12, but that readout is likely 12+ months away. For BMRN stock, the next catalysts are broader: Q4 2026 earnings (February 2027) and progress of the newly licensed Fabry ERT (HM15421/GC1134A) into the clinic.
Price Chart
Executive Summary
GALAFOLD (migalastat) is an oral pharmacological chaperone for Fabry disease, a rare genetic disorder. Originally developed and marketed by Amicus Therapeutics, it was acquired by BioMarin Pharmaceutical (BMRN) in April 2026 as part of a $4.8 billion all-cash deal. FDA-approved since August 2018, Galafold is the only oral monotherapy for Fabry disease, competing against IV enzyme replacement therapies. It generated $521.7 million in 2025 revenue (up 14% YoY) and contributed $152 million in Q3 2026, BioMarin's first full quarter of ownership. The drug has strong patent protection through 2037-2042. For a non-medical investor, Galafold is a growing commercial asset within BioMarin's diversified rare-disease portfolio, but it has no near-term binary catalyst, making it a neutral watch item rather than a standalone trading driver.
How It Works
Galafold is an oral pharmacological chaperone for Fabry disease, a rare genetic disorder where patients lack a working version of an enzyme called alpha-galactosidase A. This enzyme normally breaks down a fatty substance called globotriaosylceramide (Gb3). Galafold works by binding to the patient's own defective enzyme and stabilizing it, helping it fold into the right shape so it can travel to the lysosome (the cell's recycling center) and break down Gb3. It is taken as a capsule every other day, unlike the standard IV infusions that require a hospital visit every two weeks.
Trial Status
Galafold is FDA-approved for adults with Fabry disease and amenable GLA gene variants. A Phase 3b open-label pediatric trial (NCT06904261) is ongoing, evaluating migalastat in children aged 2 to under 12 years. The study is active but not yet recruiting per ClinicalTrials.gov records.
The Two-Sided Case
Upcoming Catalysts
- Phase 3b pediatric trial (NCT06904261) readout for children aged 2-12, likely 12+ months away
- Potential label expansion to pediatric population if trial succeeds
- Quarterly earnings reports where Galafold revenue contribution is reported (next: Q4 2026, expected February 2027)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report